HGS-ETR1 and HGS-ETR2 mAbs kill primary myeloma cells
. | . | . | . | Myeloma cell death, % . | . | |
|---|---|---|---|---|---|---|
| Patient . | Sample . | Status . | MM . | HGS-ETR1 . | HGS-ETR2 . | |
| 1 | BM | R | 5 | 0 | 0 | |
| 2 | BM | D | 4 | 0 | 0 | |
| 3 | BM | R | 20 | 75 | ND | |
| 4 | BM | R | 20 | 30 | 15 | |
| 5 | PB | R | 25 | 0 | 0 | |
| 6 | PB | R | 28 | 46 | ND | |
| 7 | PE | R | 61 | 51 | 0 | |
| 8 | PE | D | 49 | 24 | 51 | |
. | . | . | . | Myeloma cell death, % . | . | |
|---|---|---|---|---|---|---|
| Patient . | Sample . | Status . | MM . | HGS-ETR1 . | HGS-ETR2 . | |
| 1 | BM | R | 5 | 0 | 0 | |
| 2 | BM | D | 4 | 0 | 0 | |
| 3 | BM | R | 20 | 75 | ND | |
| 4 | BM | R | 20 | 30 | 15 | |
| 5 | PB | R | 25 | 0 | 0 | |
| 6 | PB | R | 28 | 46 | ND | |
| 7 | PE | R | 61 | 51 | 0 | |
| 8 | PE | D | 49 | 24 | 51 | |
Total cells (500 000 cells/mL) from either bone marrow (BM) or peripheral blood (PB) or from pleural effusion (PE) samples from patients at diagnosis (D) or relapse (R) were cultured in RPMI 1640 containing 5% FCS medium during 48 hours with or without 6 μg/mL HGS-ETR1 or HGS-ETR2. Proportion of viable myeloma cells was evaluated by FACS analysis (CD38+138+ expression).